Nifty close below 14,416 would be bearish for short-term: Vinay Rajani

Below 14,416, Nifty could slide towards next support of 14,150

markets, stock markets, stock market, trading, technical analysis, technical, trading
Vinay Rajani Mumbai
2 min read Last Updated : May 05 2021 | 8:28 AM IST
Nifty outlook
 
On May 3, 2021, Nifty bounced back sharply from the day’s low and formed bullish candle on the daily chart. On the same day, Nifty hit a low of 14,416, which happens to be the 61.8 per cent retracement of the entire pullback seen from 14,151 (Low of April 22, 2021) to 15,044 (High of April 29, 2021). Any close below 14,416 would violate the crucial support of the golden ratio and in that case, we can expect Nifty to enter in to a bearish territory. Below 14,416, Nifty could slide towards next support of 14,150. In short term, we can expect stock-specific bullish moves in mid-cap and small-cap segment and those should be traded with appropriate stoploss.

Stock picks

Buy Natco Pharma (Rs 933): | Target: Rs 1,020 | Stop-loss: Rs 850

The stock price has broken out from bullish “Pennant” pattern on the daily charts. Rising volumes during the breakout has validated the upside breakout. It has been trading above important moving average parameters, indicating uptrend on all time frames. Pharma sector has been one of the best performing sectors and is still holding its strength. The stock price has broken out from the consolidation which held for last four weeks. Indicators and oscillators like RSI, MACD and DMI have turned bullish
on short term charts

Buy HPCL (Rs 242): | Target: Rs 262 | Stop-loss: Rs 228

In the last seven weeks, the stock price has formed strong base around 228 odd levels by registering multiple bottoms. On May 4, 2021, the stock rose more than 2.5 per cent with good volumes, and surpassed the resistance of 241, which has resulted in to a breakout from the narrow consolidation, which held for seven weeks. Indicators and oscillators have turned bullish on the daily charts.
Disclaimer: Vinay Rajani is Senior Technical and Derivative Research Analyst at HDFC Securities. The analyst doesn't have any holding in the stock. Views are personal

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :MarketsMarket technicalsNatco Pharma LtdHPCLStocks to buyNifty Outlook

Next Story